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Rare variants in TREM2 cause susceptibility to late-onset Alzheimer’s disease. Here we use microarray-
based expression data generated from 101 neuropathologically normal individuals and covering 10
brain regions, including the hippocampus, to understand TREM2 biology in human brain. Using network
analysis, we detect a highly preserved TREM2-containing module in human brain, show that it relates to
microglia, and demonstrate that TREM2 is a hub gene in 5 brain regions, including the hippocampus,
suggesting that it can drive module function. Using enrichment analysis we show signiﬁcant over-
representation of genes implicated in the adaptive and innate immune system. Inspection of genes with
the highest connectivity to TREM2 suggests that it plays a key role in mediating changes in the microglial
cytoskeleton necessary not only for phagocytosis, but also migration. Most importantly, we show that
the TREM2-containing module is signiﬁcantly enriched for genes genetically implicated in Alzheimer’s
disease, multiple sclerosis, and motor neuron disease, implying that these diseases share common
pathways centered on microglia and that among the genes identiﬁed are possible new disease-relevant
genes.
 2013 Elsevier Inc. Open access under CC BY license.1. Introduction
Alzheimer’s disease (AD) is the most important cause of pre-
senile dementia worldwide. In the last 3 years, there has been
growing evidence for the importance of genetic risk factors in AD
pathogenesis with the discovery of 10 new loci from genome-wide
association studies (GWAS) (Hollingworth et al., 2011; Naj et al.,
2011), and, most recently, the identiﬁcation of heterozygous rare
variants in TREM2 as a cause of increased susceptibility to late-onset
AD (Guerreiro et al., 2012; Jonsson et al., 2012). Given that the
TREM2 variants reported are associated with an odds ratio of 2.90 to
5.05, similar to ApoE4, and given that this is an entirely new ADute and Department of Mo-
stitute of Neurology, Queen
 license.locus, these ﬁndings are of potentially high importance to the un-
derstanding of AD pathogenesis (Guerreiro et al., 2012; Jonsson
et al., 2012). However, TREM2 is yet to be extensively studied in
this context, and its functions in human brain are not fully under-
stood at present.
TREM2 encodes a trans-membrane glycoprotein, consisting of an
extracellular immunoglobulin-like domain, a transmembrane
domain, and a cytoplasmic tail. It is known to be expressed on the
cell membrane of a subset of myeloid cells, including dendritic cells,
osteoclasts, tissue macrophages, and, most importantly for AD,
microglia, the resident macrophages of the central nervous system
(Colonna, 2003). Since TREM2 itself has no intracellular signaling
motif, it is thought to be completely dependent on the adaptor
protein TYROBP (also known as DAP12) for its downstream effects.
Consistent with this view is the fact that homozygous loss-of-
function mutations in either TREM2 or TYROBP result in
NasueHakola disease (Online Mendelian Inheritance in Man
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psychotic symptoms, and progressive presenile dementia (Paloneva
et al., 2002). Upon TYROBP stimulation, an ITAM-src kinase-
signaling pathway is initiated leading to cellular activation via a
range of downstream cascades (Linnartz et al., 2010) and among
other possible functions, phagocytosis. Although the endogenous
ligand of TREM2 remains unknown, TREM2 has been shown to
recognize lipopolysaccharides in the cell wall of bacteria and, on
activation, triggers the phagocytic uptake of bacteria and the
release of reactive oxygen species (Daws et al., 2003; N’Diaye et al.,
2009). Other studies have implicated TREM2 in the phagocytosis of
apoptotic material both in vitro and in experimental autoimmune
encephalomyelitis, an animal model for multiple sclerosis. The
build-up of apoptotic material and the inability of microglia with
reduced TREM2 expression to clear it may lead to a frustrated pro-
inﬂammatory phenotype, which would explain why microglia with
reduced TREM2 expression, when challenged with apoptotic ma-
terial also had increased expression of pro-inﬂammatory cytokines
(Stuart et al., 2003).
Despite this information, there is clearly still a great deal that we
do not yet know about TREM2, and in particular, there is only
limited information about its functions in the human brain. Un-
derstanding the predominant biological functions of TREM2 in the
brain is clearly of immense importance in the identiﬁcation of po-
tential therapeutic targets for AD and new candidate genes. In this
study, we use a systems-biology approach (Lee et al., 2004; Stuart
et al., 2003), based on whole-transcriptome gene expression anal-
ysis, to identify co-expressed genes with TREM2 and to begin to
address these questions in human brain tissue. We expression-
proﬁled 788 brain samples sampled from 101 neurologically and
neuropathologically normal individuals (10 distinct brain regions
each) as part of the UK Human Brain Expression Consortium
(UKBEC), and used weighted gene co-expression network analysis
(WGCNA) to group genes into modules in an unsupervised manner
(Langfelder and Horvath, 2008; Oldham et al., 2006; Oldham et al.,
2008; Zhang and Horvath, 2005). A large and growing body of ev-
idence now exists to suggest that this approach is extremely useful
in identifying modules of biologically related genes that are not just
co-expressed but co-regulated (Konopka et al., 2011; Oldham et al.,
2008; Rosen et al., 2011; Winden et al., 2009). In this article,
we focus our analysis on the TREM2-containing modules and
compare through preservation statistics the overlap between
TREM2-containing modules in different brain regions and different
data sets to better understand the function of this gene and its
relationship to other known AD-related genes.
2. Methods
2.1. Human brain samples and analysis of Affymetrix Human Exon
1.0 ST array
Brain samples were collected by the Medical Research Council
(MRC) Sudden Death Brain and Tissue Bank (Millar et al., 2007),
Edinburgh, UK. All individuals were conﬁrmed to be neuro-
pathologically normal by histology performed on sections prepared
from parafﬁn-embedded brain tissue blocks, and the diagnosis was
determined by a consultant neuropathologist. All samples had fully
informed consent for retrieval and were authorized for ethically
approved scientiﬁc investigation (Research Ethics Committee
number 10/H0716/3).
Total RNA was isolated from human post-mortem brain tissues
using the miRNeasy 96 well kit (Qiagen, Manchester, UK). The
quality of total RNAwas evaluated by the 2100 Bioanalyzer (Agilent
Technologies, Wokingham, UK) and RNA 6000 Nano Kit (Agilent
Technologies, Wokingham, UK) before processing with the AmbionWT Expression Kit and Affymetrix GeneChip Whole Transcript
Sense Target Labeling Assay, and hybridization to the Affymetrix
Exon 1.0 ST Arrays (Affymetrix UK Ltd, High Wycombe, UK)
following the manufacturers’ protocols. Hybridized arrays were
scanned on an Affymetrix GeneChip Scanner 3000 7G (Affymetrix
UK Ltd, High Wycombe, UK) and visually inspected for hybridiza-
tion artefacts. Further details regarding tissue collection, RNA
isolation, quality control, and processing have been previously re-
ported (Trabzuni et al., 2011).
All arrays were pre-processed using Robust Multi-array Average
(quantile normalization, probe set summary by median polish)
with GC background correction (GC-RMA) algorithm (Wu et al.,
2004) in Partek Genomics Suite v6.6 (Partek Inc, St. Louis, MO).
After re-mapping the Affymetrix probe sets onto human genome
build 19 (GRCh37) as documented in the Netaffx annotation ﬁle
(HuEx-1_0-st-v2 Probeset Annotations, Release 31), we restricted
analysis to probe sets that had gene annotation and contained at
least 3 probes that hybridized uniquely to a genome position. The
resulting expression data were corrected for individual effects
(within which are nested post-mortem interval, brain pH, sex, age
at death, and cause of death) and experimental batch effects (date
of hybridization). Transcript-level expression was calculated for
26,993 genes usingWinsorized means (Winsorizing the data below
10% and above 90%). We further restricted to 15,409 transcripts that
passed the Detection Above Background (DABG) criteria (p < 0.001
in at least 50% of samples in at least 1 brain region), had a coefﬁcient
of variation>5%, and expression values of at least 5 in samples in at
least 1 brain region.
2.2. Analysis of publicly available GEO data sets
Human microarray data sets were downloaded from the Gene
Expression Omnibus (GEO; (Edgar et al., 2002)) and ArrayExpress
(Parkinson et al., 2011) repositories. The accession numbers of the
data sets used were GSE30272 (human brain tissue, Illumina Hu-
man 49K Oligo array [HEEBO-7 set], 23), E-MTAB-945 (monocytes,
Illumina HumanHT-12 v4.0 expression beadchip (Fairfax et al.,
2012), E-TABM-733 (macrophages, Affymetrix GeneChip Human
Genome U133 Plus 2.0 (Smith et al., 2009), and GSE34151 (dendritic
cells, Illumina HumanHT-12 v4.0 expression beadchip, 26). In the
case of all 4 data sets, we restricted our analysis to probes with gene
annotation and evidence of detection above background. With re-
gard to the 2 Illumina HumanHT-12 v4.0 data sets, gene annotation
was based on the re-mapping of probes as performed by the
ReMOAT pipeline (Barbosa-Morais et al., 2010) and probes were
required to pass a detection p value of <0.01 in at least 50% of
samples in a given data set. In the case of the macrophage data set
generated using the Affymetrix GeneChip Human Genome U133
Plus 2.0, gene annotation was based on the current Netaffyx
annotation ﬁle (HG-U133_Plus_2.na33.annot.csv), and probes were
required to pass a detection p-value of <0.01 in at least 50% of
samples with the data set. Finally, in the case of the brain data set
(GSE30272), gene annotation was based on the annotation ﬁles
provided within GEO, and further detection-based probe ﬁltering
was performed as described by Colantuoni et al. (Colantuoni et al.,
2011). In all cases, the resulting expression data were corrected for
experimental batch effects and individual effects (including sex and
age when available).
2.3. Identiﬁcation and removal of outlier samples for network
analyses
Gene co-expression analyses are particularly sensitive to the
presence of outlier samples, and therefore rigorous quality control
procedures were used to ensure the highest possible level of quality
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clustering the samples using hierarchical clustering with Euclidean
distance as the distance measure. Transcripts clusters showed no
relation with other covariates (e.g., age, gender, cause of death,
post-mortem interval, pH). We also conﬁrmed that the majority of
the identiﬁed outliers had low interarray correlation, which is
deﬁned as the Pearson correlation coefﬁcient of the expression
levels for a given pair of transcripts using all available data available
(i.e., <3 standard deviations [SDs] of the average interarray corre-
lation). After outlier removal, we repeated the process to check for
additional outliers.
2.4. Network construction
We followed a step-by-step network construction and module
detection. The network was constructed from the pairwise Pearson
correlations between all genes, raising these correlations to a power
of 12 while maintaining the information on the correlation signs
between genes, thus constructing a “signed” network (Mason et al.,
2009). Under this design, only positive correlations among genes
are used to construct the network. The selected power used to
weight the correlations between genes was chosen to recapitulate
scale-free topology (Zhang and Horvath, 2005).
Topological overlap measure (TOM), a pairwise measure of node
similarity (i.e., how close the neighbors of a gene are to the
neighbors of the other gene)was then calculated. Unlike correlation
or adjacency measures, which consider each pair of genes in
isolation, TOM considers each pair of genes in relation to all other
genes in the network, and it reﬂects the relative interconnectedness
of 2 nodes within their local neighbourhood. The TOM measure
allows us to create more robust co-expression relationships (Yip
and Horvath, 2007), serving as a ﬁlter to exclude spurious or iso-
lated connections during network construction.
Then, by deﬁning a dissimilarity matrix based on TOM (1-TOM),
and creating a hierarchical clustering tree based on this dissimi-
larity matrix, a dynamic tree-cutting algorithm was used to “cut”
each dendrogram and deﬁne an initial set of modules for each
network as branches of the cluster trees (the minimummodule size
was arbitrarily set to 30 genes). After an initial set of modules was
created, correlations among module eigengenes (MEs), deﬁned as
the ﬁrst principal component of the expressions of the genes within
the module, are used to merge close modules (we choose a height
cut of 0.1 of the ME dendrogram, corresponding to correlation of
0.9, to merge modules). MEs summarize the characteristic expres-
sion pattern of a module, and modules with very similar expression
proﬁles will show highly correlated eigengenes. This procedure
allows the identiﬁcation of modules of densely interconnected,
coexpressed genes (Oldham et al., 2006; Ravasz and Barabasi, 2003;
Zhang and Horvath, 2005), and has been shown to be placing
functionally related genes into groups (Eisen et al., 1998).
2.5. Preservation analysis
To validate module construction for a reference network, it is
desirable to show that modules are reproducible (or preserved) in
an independent network. To this end, a simple cross-tabulation
analysis of module memberships, and the related Fisher’s exact
test p value can be calculated. In general, to determine whether a
module found in a reference data set can also be found in a test data
set, module preservation statistics implemented in the WGCNA R
software can be used.
For each pair of brain tissues, the overlap between all modules
was calculated along with the probability of observing such overlap
by chance. The signiﬁcance of module overlap was assessed using a
Fisher’s exact test (also known as hypergeometric test) for each ofthe pairwise overlap. To account for multiple comparisons, a Bon-
ferroni correction was applied on the basis of the number of
modules in the comparison networks.
To validate modules consistency across tissues, and to evaluate
speciﬁcally howwell the TREM2-containingmodules were preserved
across tissues, we calculated a composite Z summary statistic that
aggregates different module preservation statistics (Langfelder et al.,
2011). The composite Z summary statistic can be used to determine
whethermodule nodes remain highly connected in the test network,
and to determine whether the connectivity pattern between nodes
in the reference network is similar to that in the test network. We
used a permutation-based procedure in WGCNA to calculate a
Z summary for each module (speciﬁcally, randomly permuting the
module labels in the test network and calculate corresponding
preservation statistics). The higher the preservation Z summary is for
a given module in a speciﬁc brain tissue, the stronger the evidence
that the module is preserved in another brain region. Under the null
hypothesis of no module preservation, the preservation Z summary
follows an approximately standard normal distribution, and
comprehensive simulation studies led to the following thresholds: a
module shows no evidence of preservation if its Z summary is less
than 2; a Z summary greater than 5 (or 10) indicates moderate
(strong) module preservation (Langfelder et al., 2011).
2.6. Network connectivity and module memberships
For each network the whole network connectivity (also known
as “degree”) for all genes can be calculated, and it describes the
relative importance of each gene in the network (Zhang and
Horvath, 2005). To identify the most highly connected, or most
central genes within eachmodule, referred to as “hubs”, measure of
module memberships (MMs) can be used. MMs are derived by ﬁrst
summarizing the expression levels of all genes in each module by
the corresponding ME (that is, the ﬁrst principal component ob-
tained by singular value decomposition). MMs for each gene with
respect to each module are deﬁned as the Pearson correlation be-
tween the expression level of a given gene and the module ME. This
quantity describes the extent to which a gene “belongs” to a
module. Values of MM range from1 (perfect anti-correlation) to 1
(perfect correlation). We used MMs to characterize the importance
of TREM2 within each module for each brain tissue.
2.7. Gene set enrichment analysis with DAVID
To evaluate the biological and functional relevance of coex-
pressed genes within the TREM2-containing modules, we used
DAVID v6.7 (http://david.abcc.ncifcrf.gov/), the database for anno-
tation, visualization, and integrated discovery (Huang da et al.,
2009b). We examined the overrepresentation (i.e., enrichment) of
the 3 Gene Ontology (GO) categories (biological processes, cellular
components, and molecular function) for each list of coexpressed
genes with TREM2 for each tissue by comparing numbers of sig-
niﬁcant genes annotated with this biological category with chance.
3. Results
3.1. Regional distribution of TREM2 mRNA expression in human
brain
The human data used here were provided by the UK Human
Brain Expression Consortium (Trabzuni et al., 2011) and consisted of
101 control post-mortem brains. All samples originated from in-
dividuals with no signiﬁcant neurological history or neuropatho-
logical abnormality, and all were collected by the MRC Edinburgh
Brain Bank (Millar et al., 2007) ensuring a consistent dissection
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able demographic details of these samples, including a thorough
analysis of their effects on array quality, is provided by Trabzuni
et al (Trabzuni et al., 2011). In brief, samples originated from in-
dividuals with amale: female ratio of 77:24 (3.2), mean age at death
of 51 years (range, 16e83 years), and modal cause of death of
ischemic heart disease (59%; full details provided in Supplementary
Tables 1 and 2). Up to 10 brain regions were sampled from each
individual, resulting in 788 Affymetrix Human Exon 1.0 ST arrays
after rigorous removal of outliers. The regions sampled were BA 8
and 9 (frontal cortex [FCTX]), BA17 (occipital cortex [OCTX]), BA 21
and 22 (temporal cortex [TCTX]), intralobular white matter
(WHMT), hippocampus (HIPP), thalamus (at the level of the lateral
geniculate nucleus (THAL), putamen (at the level of the anterior
commissure [PUTM]), substantia nigra (SNIG), the inferior olivary
nucleus (sub-dissected from the medulla [MEDU]) and the cere-
bellar cortex (CRBL).Fig. 1. Regional and age-related variability in TREM2 expression in human brain. (A) Regiona
levels for TREM2 in 10 brain regions, based on microarray experiments and plotted on a log
Age-related changes in TREM2 expression in substantia nigra, medulla, and thalamus, basedFig. 1A shows the regional distribution of mRNA expression for
TREM2 at the gene level for human brains. This demonstrated
signiﬁcant regional differences in TREM2 gene expression with a
4.96-fold difference (paired t test p value ¼ 6.63  1033) between
white matter (the highest-expressing region) and cerebellum
(lowest-expressing region). Given the age-dependent and sex-
biased incidence of Alzheimer’s disease (AD), we investigated
TREM2 expression in each brain region for age- or sex-related
changes in expression, while accounting for the potential con-
founding effects of post-mortem interval, cause of death, brain pH,
and experimental batch effects. We found suggestive age-related
increases in TREM2 expression in 3 brain regions: MEDU (p ¼
0.043), THAL (p ¼ 0.037), and SNIG (p ¼ 0.048, Fig. 1B). Although
these ﬁndings could not be replicated using the only other publicly
available data set covering these brain regions (Kang et al., 2011)
(Supplementary Fig. 1), it should be noted that this particular data
set contains samples originating from only 18 adults, whereas ourl distribution of TREM2mRNA expression in human brain: box plot of mRNA expression
2 scale (y-axis). Whiskers extend from the box to 1.5 times the interquartile range. (B)
on microarray experiments and plotted on a log2 scale (y-axis).
Table 1
Module detection in each brain region: Sample sizes, number of modules, and
modules sizes, by brain tissue
Brain region Samples after
outlier removal (n)
Modules (n) Module size
(range)
CRBL 76 23 61e5373
FCTX 83 23 71e5072
HIPP 86 32 46e4193
MEDU 88 17 60e4342
OCTX 77 34 52e3705
PUTM 77 20 38e6729
SNIG 65 13 118e4072
TCTX 72 22 78e2908
THAL 81 19 56e2771
WHMT 83 17 69e4387
Total 788
Brain regions are available regions for human brains.
Key: CRBL, cerebellum; FCTX, frontal cortex; HIPP, hippocampus; MEDU, medulla
(speciﬁcally inferior olivary nucleus); OCTX, occipital cortex (speciﬁcally primary
visual cortex); PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cortex;
THAL, thalamus; WHMT, intralobular white matter.
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was no evidence of sex-biased expression of TREM2 in any brain
region.
3.2. Weighted Gene Co-expression Network Analysis identiﬁes a
TREM2-containing module, which is highly preserved in all brain
regions
To gain insights into the functional organization of the brain
transcriptome, we used the WGCNA package (Langfelder and
Horvath, 2008; Zhang and Horvath, 2005) and focused on TREM2.
This analytic approach uses the degree of gene neighbourhood
sharing, as deﬁned on the basis of co-expression relationships, to
identify groups ormodules of genes that are highly co-expressed and
(by implication) functionally related (Geschwind and Konopka,
2009; Miller et al., 2008; Oldham et al., 2008; Winden et al., 2009).
We used WGCNA to analyze gene expression data on 15,409 tran-
scripts equating to 13,706 genes (passing ﬁltering as described in
Methods) to construct signed weighted gene co-expression net-
works for each of the 10 brain regions (see Methods). On this basis,
we identiﬁed between 13 and 34 modules per region, depending on
the brain region (Table 1). Whole network connectivity for each
tissue and TREM2-speciﬁc connectivity is summarized in the
Supplementary Table 3. Before proceeding to investigate TREM2-
containing modules, we checked the consistency of all the identiﬁed
modules across the 10 brain regions and particularly within the 3
available neocortical regions (FCTX, TCTX, and OCTX). As would be
expected, we observed particularly high module conservation
among the 3 cortical regions, as shown in (Fig. 2A and B). These
ﬁndings are consistent with the study by Oldham et al. (Oldham
et al., 2008) that showed similar co-expression preservation in 3
different regions in the brain.
Having established the robustness of the whole network, we
checked the preservation statistics for the TREM2-containing
modules across all 10 brain regions. Table 2 shows the number of
shared genes (and percentages) among the TREM2-containing
modules from each region. We identiﬁed 77 genes present in all 10
regional TREM2-containing modules. We used Fisher’s exact to test
for signiﬁcant overlap in module membership and found that all 45
pairwise comparisons were highly signiﬁcant (p < 1.1  103 ¼
0.05/45 after Bonferroni correction), indicating a high overlap in
module membership among all TREM2-containing modules. We
also used a permutation test procedure implemented in the
WGCNA R package to evaluate preservation across multiple tissues.
This procedure produces a summary preservation Z statistic
(plotted in Fig. 3) that takes into account connectivity patterns
between nodes, not just overlaps in module membership on cross-
tabulation (see Methods) (Langfelder et al., 2011). We found that
the TREM2-containing module is highly conserved in all brain
regions.
3.3. Independent human brain dataset replicates gene membership
found within the TREM2-containing module
For validation purposes, we used an independent and publicly
available dataset (Colantuoni et al., 2011), collected from human
dorsolateral prefrontal cortex in an extensive series of samples
collected from fetal development through aging (GSE30272). We
restricted our analysis to adult brain samples (individuals aged 16
years and more, n ¼ 175) to maximize comparability with the
UKBEC dataset. Using the same parameters for network construc-
tion as were applied to the UKBEC data set, we constructed a signed
WGCNA for 15,250 transcripts (representing 10,740 gene symbols).
On this basis, we identiﬁed 46 modules (size ranging between 37
and 1,969 transcripts; whole network connectivity between 4.6 and146.0). The TREM2-containingmodule in this dataset contained 255
unique genes symbols (representing 315 transcripts). We observe a
highly signiﬁcant overlap between genes in this module and the
genes within the corresponding TREM2-containing module in the
frontal cortex of the UKBEC dataset. More speciﬁcally, we observe
95 overlapping gene symbols (2.2 genes expected by chance,
Fisher’s exact test p value <7  10142).3.4. TREM2-containing module is partially preserved in blood-
derived macrophages
Given the importance of TREM2 in the pathogenesis of AD,
there is an urgent need to better understand its functions.
Although ideally this would be achieved by studying adult human
microglia, practically this is challenging. This led us to assess the
validity of using other more accessible and potentially relevant
human cell types, namely monocytes, macrophages, and dendritic
cells. To do this, we used publicly available human whole-genome
gene expression data generated on the Illumina HT12 v4 beadchip
array and the Affymetrix U133 Plus 2.0 array with large numbers
of healthy individuals: (monocytes, E-MTAB-945, N ¼ 188 (Fairfax
et al., 2012); macrophages, E-TABM-733, N ¼ 16 (Smith et al.,
2009); dendritic cells, GSE34151, N ¼ 69 (Barreiro et al., 2012)).
In each case, we started by checking the evidence for TREM2
expression in these cell types. In keeping with the existing liter-
ature (on the basis of microarray data), we were unable to
convincingly detect TREM2 expression in monocytes (percentage
of samples passing a detection p value of 0.01 ¼ 4.1%), but could
detect expression in nonstimulated macrophages and dendritic
cells.
We next used WGCNA to assess gene expression data on 11,658
genes in macrophages and 8300 genes in dendritic cells (passing
ﬁltering as described in Methods) to construct signed weighted
gene co-expression networks (see Methods). Focusing on the
TREM2-containing module in macrophages and dendritic cells, we
found that TREM2 had high module membership (macrophages
and dendritic cells, 61th quantile) but was not a “hub” gene in
either cell type. We next assessed preservation of the TREM2-
containing module across the 2 cell types and in post-mortem
human brain tissue. We found that whereas there was no signiﬁ-
cant preservation of the TREM2-containing module between den-
dritic cells and macrophages (Fisher’s exact test p value ¼ 0.38) or
dendritic cells and brain (Fisher’s exact test p value ¼ 0.77), there
were 13 genes in common between the TREM2-containing
Fig. 2. Evidence of high conservation of modules across brain cortical regions. (A) Hierarchical clustering dendrogram for FCTX and equivalent module assignment colours for all 3
cortical regions (frontal cortex [FCTX], temporal cortex [TCTX], occipital cortex [OCTX]). (B) Preservation statistics (Z summary) among the 3 cortical regions, i.e. FCTX/OCTX shows
the preservation Z summary statistics for the FCTX modules in OCTX.
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by chance, Fisher’s exact test p ¼ 4.52  103). Although this does
suggest signiﬁcant preservation of the TREM2-containing module
across these 2 tissue/cell types, it is much weaker than that
observed between the 2 brain data sets analyzed (Fisher’s exact
test p value <7  10142).3.5. TREM2-containing modules in human brain correspond to a
microglial signature
Consistent with the expression of TREM2 in microglia, the known
microglia markers CX3CR1, ITGAM, AIF1, FCER1G, and CD68 were
present within the TREM2-containing module in all brain regions
Table 2
Number of genes in the TREM2-containing module for each tissue and overlap with TREM2-containing modules in other tissues
Tissue Genes in
module (n)
CRBL FCTX HIPP MEDU OCTX PUTM SNIG TCTX THAL WHMT
CRBL 226 d 132 (58.4%) 145 (64.2%) 208 (92%) 147 (65%) 113 (50%) 196 (86.7%) 151 (66.8%) 153 (67.7%) 218 (96.5%)
FCTX 151 132 (87.4%) d 117 (77.5%) 144 (95.4%) 127 (84.1%) 100 (66.2%) 143 (94.7%) 122 (80.8%) 125 (82.8%) 149 (98.7%)
HIPP 175 145 (82.9%) 117 (66.9%) d 162 (92.6%) 136 (77.7%) 101 (57.7%) 158 (90.3%) 134 (76.6%) 128 (73.1%) 169 (96.6%)
MEDU 560 208 (37.1%) 144 (25.7%) 162 (28.9%) d 176 (31.4%) 122 (21.8%) 283 (50.5%) 196 (35%) 176 (31.4%) 426 (76.1%)
OCTX 186 147 (79%) 127 (68.3%) 136 (73.1%) 176 (94.6%) d 106 (57%) 162 (87.1%) 139 (74.7%) 135 (72.6%) 176 (94.6%)
PUTM 133 113 (85%) 100 (75.2%) 101 (75.9%) 122 (91.7%) 106 (79.7%) d 119 (89.5%) 106 (79.7%) 104 (78.2%) 125 (94%)
SNIG 377 196 (52%) 143 (37.9%) 158 (41.9%) 283 (75.1%) 162 (43%) 119 (31.6%) d 173 (45.9%) 165 (43.8%) 294 (78%)
TCTX 257 151 (58.8%) 122 (47.5%) 134 (52.1%) 196 (76.3%) 139 (54.1%) 106 (41.2%) 173 (67.3%) d 134 (52.1%) 194 (75.5%)
THAL 187 153 (81.8%) 125 (66.8%) 128 (68.4%) 176 (94.1%) 135 (72.2%) 104 (55.6%) 165 (88.2%) 134 (71.7%) d 177 (94.7%)
WHMT 728 218 (29.9%) 149 (20.5%) 169 (23.2%) 426 (58.5%) 176 (24.2%) 125 (17.2%) 294 (40.4%) 194 (26.6%) 177 (24.3%) d
Percentages are quoted as proportion of the number of genes in the TREM2-containing module in the tissue indicated in the rows. Overlaps were tested using Fisher’s exact test
at a Bonferroni-adjusted value of p < 1.1  103 ¼ 0.05/45. All overlaps were found to be highly signiﬁcant.
Key: CRBL, cerebellum; FCTX, frontal cortex; HIPP, hippocampus; MEDU, medulla (speciﬁcally inferior olivary nucleus); OCTX, occipital cortex (speciﬁcally primary visual
cortex); PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cortex; THAL, thalamus; WHMT, intralobular white matter.
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these genes, we measured their module membership (MM), as
deﬁned by how well the expression pattern of each gene within the
module correlates with the ﬁrst principal component of gene
expression for that module, termed the module eigengene (see
Methods). In all cases, the mean MM across all brain regions was
above the median (CX3CR1 56th; ITGAM 93rd; AIF1 82nd, FCER1G 78th,
and CD68 97th quantile). These ﬁndings and, in particular, the high
MM of microglia markers, suggest that the TREM2-containing mod-
ules in human brain strongly relate to the gene expression signature
ofmicroglia. It should alsobenoted that searching for genes related to
the major neurotransmitter signaling systems (namely gluta-
matergic, GABAergic, dopaminergic, cholinergic, serotonergic, hista-
minergic, glycinergic, purinergic, adenosinergic, noradrenergic, and
adrenergic) demonstrated only the presence of the purinergic andFig. 3. Preservation statistic (Z summary) of each regional TREM2-containingadenosinergic receptors (ADORA3, P2RX4, P2RY12, and P2RY13)within
the TREM2-containing modules, suggesting that this module is very
unlikely to relate to any neuronal population. Similarly, no oligo-
dendrocyte markers (OLIGO1, OLIGO2, MAG, MOG, and MOBP) were
detected and of the astrocytemarkers (GFAP, S100B, and ALDOC); only
GFAP (a marker of activated astrocytes) was present in the TREM2-
containing module in white matter (quantile ¼ 38th).
We also investigated gene membership within the TREM2-
containing modules to see if we could infer the predominant
microglial activation state relevant to these modules. Despite the
distinct origin of microglia (Ginhoux et al., 2010), these cells (like
peripheral macrophages) have been classiﬁed as M1- or M2-like
(with sub-classiﬁcation of M2a, M2b, and M2c). Whereas the M1
phenotype is adopted in response to activation with lipopolysac-
charide or interferon-g and denotes a pro-inﬂammatory state, themodule across the equivalent modules in all other human brain regions.
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2003). We investigated features of 62 genetic markers (as
described elsewhere (David and Kroner, 2011); Supplementary
Table 4) of the M1 and M2 activation states. Of these, 17 genes
were members of at least 1 of the regional TREM2-containing
modules. These included the following: 5 genes associated with the
M2a activation state (IGF1, PDGFB, PDGFC, TGFB1, andMSR1); 7 genes
contributing to the major histocompatibility complex (MHC) class II
protein complex which has been associated with both the M1 and
M2b activation state (CD74, HLA-DMA, HLA-DMB, HLA-DPA1, HLA-
DPB1, HLA-DQA2, and HLA-DRA); 4 genes associated with the M1
activation state (FCGR2A, FCGR2B, FCGR3B, and CXCL10); and ﬁnally
CD86, which (like MHC class II) has been associated with both the
M1 and M2b states. Because we detected markers for both the M1
and M2 activation states, we used MM as a basis for hierarchical
clustering of genes to better assess microglia state in different brain
regions. These data are presented in Fig. 4 and show that the
dominant markers (based on MM) were members of the MHC class
II protein complex, and that markers of the M2a complex were
detected only in white matter and, to a lesser extent, the medulla.
3.6. TREM2 is a “hub” gene within the TREM2-containing module in
the hippocampus and white matter among other brain regions
Within each TREM2-containing module, WGCNA allows us to
identify the most highly connected genes, or central genes, referred
to as “hubs,” as deﬁned by a highMM (as described above). The MM
for TREM2 was above the median in all brain regions, including the
replication data set (88th quantile within this module). In fact,
TREM2 was in the top 90th quantile in the hippocampus, white
matter, medulla, putamen, and substantia nigra (Table 3), indicating
that TREM2 is clearly a hub gene in these 5 tissues.
Based on this deﬁnition of “hub,” namely, MM in the top 90th
quantile in at least 5 brain regions, we identiﬁed a further 15 genes
of interest: APBB1IP, C3AR1, CYBB, DOCK2, DOCK8, NCKAP1L,
ADORA3, CD68, FYB, PTPRC, TBXAS1, ADAM28, ITGAM, METTL9, and
CD84. This would suggest that although 980 genes are identiﬁed as
members of the TREM2-containing module across all 10 brain re-
gions, TREM2 is actually part of a select group of genes driving
module function.Fig. 4. Hierarchical clustering of microglial markers across all 10 brain regions based on mod
regional TREM2-containing module are depicted in gray (and have a module membership o3.7. TREM2-containing modules in the human brain are enriched
for genes implicated not only in the innate but also the adaptive
immune system
Gene Ontology (GO) enrichment analysis was performed on the
TREM2-containing modules in each brain region using the Database
for Annotation, Visualization and Integrated Discovery (DAVID)
(Huang da et al., 2009a, 2009b). The results of this analysis are
summarized in Table 4 and provided in full in Supplementary
Table 5. This demonstrated that the TREM2-containing modules
from all 10 brain regions were highly enriched for genes related to
immune response (minimum Bonferroni-corrected p value ¼ 1.65 
1047). This ﬁnding is clearly consistent with the known expression
of TREM2 on microglia (Colonna, 2003). In keeping with the existing
literature, GO enrichment analysis provided strong evidence for a
role for TREM2 in the innate immune response (minimum
Bonferroni-corrected p value ¼ 3.44  1012) and, more speciﬁcally,
lysosome activity in all brain regions. This was demonstrated by the
signiﬁcant enrichment of genes classiﬁed byGO to lytic vacuoles and
lysosomes in 7 of the 10 regional TREM2-containing modules
including the hippocampus, frontal cortex, and white matter (min-
imum Bonferroni-corrected p value¼ 2.96 104). Interestingly, we
found that despite the weak (but signiﬁcant) preservation of the
TREM2-containing module in macrophages, there was a signiﬁcant
overrepresentation of genes related to lytic vacuoles and lysosomes
in these data too (minimum Bonferroni-corrected p value in human
brain ¼ 2.96  104; macrophages ¼ 2.10  102), suggesting that
modulation of lysosome activity is a well-preserved TREM2-related
function though the underlying gene network may be different
(Supplementary Fig. 2).
We also found evidence in support of links to the adaptive im-
mune system. There was signiﬁcant enrichment of genes involved
in the regulation of lymphocyte activation in all 10 regional TREM2-
containing modules (minimum Bonferroni-corrected p value ¼
6.42  107) with evidence for interactions with both B and T cells.
The GO term “B cell mediated immunity” was signiﬁcant in all 10
regional TREM2-containing modules (minimum Bonferroni-
corrected p value ¼ 9.16  105), whereas “T cell activation” was
featured in 9 of 10 modules (minimum Bonferroni-corrected p
value ¼ 8.75  105). Other major microglial functions were alsoule membership. Genetic markers of microglial state that were not detected in a given
f 0).
Table 3
Summary of the module membership (MM) within the TREM2-containing modules for each brain tissue for TREM2 and all transcripts assigned to TREM2-containing modules
Data set Genes in module (n) TREM2 Summary statistics of the MM of the transcripts within the TREM2-containing
module
MM 1epth quantile Min First quartile Median Mean Third quartile Max
UKBEC
CRBL 226 0.82 0.17 0.29 0.55 0.68 0.67 0.78 0.95
FCTX 151 0.78 0.26 0.32 0.64 0.72 0.71 0.78 0.94
HIPP 175 0.89 0.09 0.20 0.68 0.76 0.74 0.83 0.95
MEDU 560 0.92 0.03 0.17 0.51 0.68 0.65 0.8 0.95
OCTX 186 0.76 0.25 0.25 0.55 0.66 0.65 0.76 0.92
PUTM 133 0.88 0.05 0.4 0.64 0.73 0.71 0.79 0.92
SNIG 377 0.88 0.07 0.31 0.55 0.67 0.67 0.8 0.94
TCTX 257 0.79 0.15 0.22 0.57 0.66 0.66 0.75 0.94
THAL 187 0.86 0.12 0.41 0.63 0.74 0.71 0.81 0.94
WHMT 728 0.9 0.03 0.03 0.43 0.6 0.59 0.75 0.95
Colantuoni et al. 315 0.8 0.12 0.20 0.51 0.62 0.62 0.74 0.92
1epth quantile¼ rankMM(TREM2)/module size. The pth quantiles>90th quantile are highlighted in boldface type. For these tissues, TREM2 shows amajor rolewithin themodule
(hub gene).
Key: CRBL, cerebellum; FCTX, frontal cortex;HIPP, hippocampus;MEDU,medulla (speciﬁcally inferior olivarynucleus); OCTX, occipital cortex (speciﬁcally primary visual cortex);
PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cortex; THAL, thalamus; UKBEC, UK Human Brain Expression Consortium; WHMT, intralobular white matter.
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tation via MHC class II” appearing as a highly signiﬁcant term in all
10 regional TREM2-containing modules (minimum Bonferroni-
corrected p values ¼ 1.15  105) and “the regulation of cytokine
production” signiﬁcant in 8 of 10 modules (minimum Bonferroni-
corrected p values ¼ 7.68  107). Investigating the TREM2-con-
taining modules for the enrichment of GO molecular functions,
highlighted the involvement of G-protein-coupled nucleotide re-
ceptor signalling in 8 of 10 brain regions (including theTable 4
Summary of the results of GO enrichment analysis performed on the TREM2-containing
Key: CRBL, cerebellum; FCTX, frontal cortex; HIPP, hippocampus; MEDU, medulla (spec
cortex); PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cortex; THAL, thalamuhippocampus, Bonferroni corrected p value ¼ 3.46  104). Inter-
estingly, genes related to purinergic signaling featured more
prominently in the TREM2-containing modules than those involved
in IgG binding, cytokine signaling, or MHC class II receptor activity.
3.8. Insights into TREM2-related signaling pathways
To obtain insights into TREM2-related signaling, we chose to
focus on a “core set” of 156 TREM2-related genes (deﬁned on themodules in each brain region
iﬁcally inferior olivary nucleus); OCTX, occipital cortex (speciﬁcally primary visual
s; WHMT, intralobular white matter.
Fig. 5. Enrichment of “core” TREM2-related genes within Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. (A) “Fc gamma R-mediated phagocytosis” pathway with
proteins/complexes containing “core” TREM2-related genes highlighted with a red box (Kanehisa et al., 2012; Kanehisa and Goto, 2000). (B) “Systemic lupus erythematosus”
pathway with proteins/complexes containing “core” TREM2-related genes highlighted with a red box (Kanehisa et al., 2012; Kanehisa and Goto, 2000).
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brain region). We used this set to look for enrichment of canonical
gene sets deﬁned by the Kyoto Encyclopedia of Genes and Genomes
(KEGG) and relating to known pathways (Kanehisa and Goto, 2000;
Kanehisa et al., 2012).We identiﬁed 11 pathways with a Bonferroni-
corrected p value of <0.05. After accounting for signiﬁcant overlaps
in the gene memberships of these pathways (as calculated withintheMolecular Signatures Database v3.1, http://www.broadinstitute.
org/gsea/msigdb/index.jsp), we identiﬁed 2 independent path-
ways of interest, the “Fc gamma R-mediated phagocytosis” (Bon-
ferroni-corrected p value ¼ 4.72  104) and “Systemic lupus
erythematosus” pathways (Bonferroni-corrected p value ¼ 3.46 
104). These are depicted in Fig. 5A and B with the proteins/com-
plexes containing “core” TREM2-related genes highlighted with a
Fig. 6. Insights into TREM2-related signaling using data-driven network constructions and information provided by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analysis. (A) Network depiction of the TREM2-containing module in HIPP, showing all genes connected with a topological overlap measure (TOM) >0.10. TREM2 is highlighted in red,
together with all of the genes that are directly connected to it, based on the TOM cut-off used. Genes that are featured in our proposed TREM2 signaling pathway are boxed in blue.
(B) Network depiction of the TREM2-containing module in CRBL, showing all genes connected with a TOM >0.10. As above, TREM2 is highlighted in red, together with the genes that
are directly connected to it, based on the TOM cut-off used. Genes that are featured in our proposed TREM2 signalling pathway are boxed in blue. (C) Proposed TREM2-signaling
pathway in human brain adapted from the KEGG pathways for “Fc gamma R-mediated phagocytosis” and “Systemic lupus erythematosus.” Genes/complexes highlighted by data-
driven network analyses are boxed in blue.
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TREM2 located on microglia might act to respond to apoptotic
material and immune complexes in their micro-environment
through the recognition of the C1Q complex and signal via the
ITAM-src-signaling pathway to initiate phagocytosis of the mate-
rial, but also potentially other processes (including antigen pre-
sentation). Because 2 ITAM-containing adaptor proteins are
members of the “core” gene set, namely FCER1G and TYROBP, in
theory at least either could associate with TREM2 protein. Similarly,on the basis of TREM2-module membership, downstream signaling
is most likely to occur through the src kinase, LYN (a member of the
“core” gene set). However, it is worth noting that HCK is a member
of the TREM2-containing module in medulla and white matter
suggesting potential regional heterogeneity in the use of src
kinases.
Because the use of canonical pathways is limited by our existing
knowledge base, we also chose to visualize gene interconnection
within the TREM2-containing module using VisANT. Connections
P. Forabosco et al. / Neurobiology of Aging 34 (2013) 2699e27142710among genes was deﬁned on the basis of TOM and genes were
“connected” if the TOM was greater than 0.10. Given the involve-
ment of TREM2 in late-onset AD, we focused on the TREM2-con-
tainingmodule in the hippocampus, a region that undergoes severe
neurodegeneration, and contrasted this with a relatively unaffected
region, the cerebellum (Fig. 6A and B). Based on a TOM of >0.10,
we identiﬁed 45 genes connected to TREM2 in hippocampus and
similarly 45 genes in cerebellum. As would be expected, both gene
lists included members already known to be part of the TREM2
intracellular signaling pathway (including TYROBP and SYK) and
many genes that were previously identiﬁed within the canonical
KEGG pathways. Interestingly, both lists also included 2 purinergic
receptors, P2RY12 and P2RY13. The P2YR12 is already known to be
expressed on microglia and has been shown to play a critical role in
the chemotactic response to ATP released by apoptotic and dying
cells (Haynes et al., 2006; Pocock and Kettenmann, 2007). In the
case of the hippocampus, this list included 9 genes (NCKAP1L,
APBB1IP, CSF1R, DOCK2, DOCK8, ITGAX, C1QB, LAPTM5, and METTL9)
with “direct” connection to TREM2 (as marked in pink and using the
cut off of TOM >0.10). Only 2 such genes were identiﬁed in cere-
bellum, NCKAP1L and ITGAX. Interestingly, 5 of the genes with
“direct” connection in hippocampus have been implicated in
cytoskeletal rearrangements and cell adhesion. NCKAP1L (also
known as HEM1) encodes a member of the HEM family of tissue-
speciﬁc trans-membrane proteins and forms part of the Scar/
WAVE complex, which plays an important role in regulating cell
shape and has been shown to be essential for actin polymerization
andmyosin regulation during neutrophil chemotaxis (Weiner et al.,
2006). Similarly DOCK2 is known to be involved in remodeling of
the actin cytoskeleton required for lymphocyte migration (Sanui
et al., 2003), and the biological functions of DOCK8 include regu-
lation of cell migration and morphology (Harada et al., 2012;
Mizesko et al., 2013). APBB1IP (also known as RIAM) encodes the
Rap1-GTP-interacting adaptor molecule (RIAM) and has been
implicated in mediating changes in the actin cytoskeleton after
integrin-mediated adhesion acting through the Vav2-RhoA-ROCK-
myosin light chain pathway (Hernandez-Varas et al., 2011; Lafuente
et al., 2004). Finally, ITGAX encodes the integrin alpha X chain
protein, which forms part of the alpha X beta 2 complex that has
been implicated in the adherence of neutrophils and monocytes to
stimulated endothelium cells, and in the phagocytosis of
complement-coated particles (Hynes, 1992; Schoenwaelder and
Burridge, 1999; van Lookeren Campagne et al., 2007). Although,
the remaining 4 genes (CSF1R, LAPTM5, C1QB, and METTL9) had no
obvious common features, the identiﬁcation of CSF1R is notable, as
the TREM2-TYROBP protein complex has recently been implicated
in CSF1R signaling providing a biological basis for the high
connection between CSF1R and TREM2 (Otero et al., 2009). C1QB has
already been highlighted within the canonical pathway for “Sys-
temic lupus erythrematosus” and LAPTM5 (lysosomal protein
transmembrane 5) is a transmembrane receptor that is associated
with lysosomes. Using the information provided by both the
investigation of canonical pathways and data-driven network
construction, it is possible to build a potential TREM2-signaling
pathway for human microglia (Fig. 6C) characterized by a central
role for TREM2 in the response to C1Q-containing complexes and
ATP/ADP in the micro-environment and the subsequent cytoskel-
etal changes that are required not only for phagocytosis, but also
surveillance and chemotaxis.
3.9. Relative enrichment of genes already linked to Alzheimer’s
disease among genes within the TREM2-containing modules
The identiﬁcation of variants in TREM2 as an important cause of
late-onset Alzheimer’s disease raises the possibility that genes thatare highly co-expressed with TREM2might also be candidate genes
for AD. One way of assessing the validity of this approach is to look
at the enrichment of genes already genetically linked to AD among
genes within the TREM2-containingmodules in human brain. Using
HUGEnavigator (http://www.hugenavigator.net/HuGENavigator/
home.do) (Yu et al., 2008), which uses text mining algorithms to
search PubMed and to create an up-to-date knowledge base for
exploring genetic associations, we can identify 1499 genes that
have been linked to AD. From this list, 1004 genes were studied
within our WGCNA analysis of human brain. We looked for
enrichment of these AD-related genes within a “core set” of 156
TREM2-related genes (deﬁned on the basis of module membership
above the 80th quantile in at least 1 brain region).We found a highly
signiﬁcant enrichment of AD-related genes among the “core set” of
TREM2-connected genes (c2 test with Yates correction p value ¼
3.67  1010). Among the genes accounting for this enrichment
were MS4A6A, which is strongly implicated in AD through recent
GWAS (Hollingworth et al., 2011; Naj et al., 2011) and APBB1IP
(Morgan et al., 2007) (full details provided in Supplementary
Table 6). We used a similar approach to look for enrichment of
genes implicated in other neurological disorders, namely Parkin-
son’s disease (PD), multiple sclerosis (MS), and motor neuron dis-
ease (MND), on the basis that TREM2-related microglial activity
might be a general contributing factor in the pathogenesis of
multiple disorders (Supplementary Table 6). Although there was no
evidence for enrichment of PD-related genes (c2 test with Yates
correction p value¼ 0.92), therewas evidence for enrichment of MS
(c2 test with Yates correction p value ¼ 7.50  1015) MND-related
genes (c2 with Yates correction, p ¼ 4.85  103). These ﬁndings
suggest that among the list of “core genes,” there might be as-yet-
unidentiﬁed AD-related genes, and also (albeit indirectly) validate
previously identiﬁed AD candidate genes.
4. Discussion
The discovery of variants in TREM2 as a predisposing factor for
late-onset AD has opened up a potential new avenue for the un-
derstanding of this disease (Guerreiro et al., 2012; Jonsson et al.,
2012). To realize that potential an improved appreciation for the
“normal” function of TREM2 in the human brain is required,
particularly because increased risk is thought to be mediated
through reduced TREM2 function. To this end, we used a large
microarray data set generated from neuropathologically control
post-mortem tissue to analyze TREM2 expression, and we used
WGCNA analysis to identify highly co-expressed genes in 10 brain
regions, including the hippocampus. This approach, albeit not
without its drawbacks, allowed us to obtain insights into TREM2
function, not in an isolated cell type but in the context of whole
human brain tissue. We demonstrate that a highly preserved
TREM2-containing module of gene expression exists in all brain
regions and relates to a microglial expression signature. Impor-
tantly, TREM2 is a hub gene in this module in 5 brain regions,
including the hippocampus, suggesting that it is capable of driving
module function in these regions at least. Given that the TREM2-
containing modules were highly enriched for genes related not
only to the innate immune system (the major recognized function
of TREM2), but also the adaptive immune system widens the
functional processes related to TREM2. Furthermore, close inspec-
tion of the genes with the highest connectivity to TREM2, provided
insights intoTREM2-related signaling, suggesting that this gene has
a central role in mediating changes in the cytoskeletal structure in
response to damage-related signals (such as C1Q and ATP/ADP)
within the microglial micro-environment. Finally, we demonstrate
signiﬁcant enrichment of candidate genes for AD, MS, and, to a
lesser extent, MND within the core genes of the TREM2-containing
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share common pathways centred on microglial function and, sec-
ond, that among the list of genes identiﬁed by this study are as-yet-
unknown disease-relevant genes.
The basis of this study was microarray data generated from 788
human brain samples originating from 101 neurologically and
neuropathologically control individuals collected from a single
brain bank, the MRC Sudden Death Brain Bank in Edinburgh, and
covering 10 brain regions. These data set allowed us to conﬁdently
quantify TREM2 expression across the human brain, demonstrate
signiﬁcant regional differences, and assess age-related changes in
expression. Given that previous studies, not to mention this one,
have found that TREM2 is almost exclusively expressed onmicroglia
in human brain (Colonna, 2003), it seems likely that the regional
differences in TREM2 expression relate to regional differences in
either overall microglial density or a subpopulation of microglia.
Certainly the higher expression of TREM2 in white matter versus
gray matter samples, and the high TREM2 expression in hippo-
campus, mirror known regional differences in microglial density in
human brain (Mittelbronn et al., 2001). This interpretation of the
TREM2 expression datawould imply that the suggestive age-related
increase in TREM2 expression found in 3 brain regions may also
reﬂect changes in microglial density, again perhaps of a speciﬁc
sub-population. Although we were unable to ﬁnd evidence in
support of this expression pattern within existing publicly acces-
sible data sets, there is evidence in support of age-related increases
in microglia in the normal human brain (Conde and Streit, 2006)
and a growing literature to suggest age-related changes in micro-
glial function (Miller and Streit, 2007).
We next used WGCNA to group genes into modules that have
strongly co-varying expression patterns, to identify biologically
relevant features of the data. This approach allowed us to detect a
TREM2-containing genemodule, whichwas not only well preserved
within all 10 brain regions studied but which could also be repli-
cated in an independent human brain expression data set gener-
ated using an unrelated expression platform. In keeping with
previous published analyses, this gene module, despite the use of
heterogeneous samples (e.g., cerebellar cortex), related to a speciﬁc
cell type, namely microglia, as demonstrated by the presence of
multiple microglial markers within the TREM2-containing modules
in all human brain samples. Wewere unable to clearly establish the
predominant activation state of the microglia, with the detection of
both markers of the M1 activation state (FCGR2A, FCGR2B, FCGR3B,
and CXCL10) and M2a activation state in a subset of regions (IGF1,
PDGFB, PDGFC, TGFB1, andMSR1). This complexity is likely to arise at
least in part from the use of post-mortem brain tissue and the
related variability in the mode of death of the individuals sampled.
Although all samples originated from individuals undergoing sud-
den death, some modes of death may be associated with speciﬁc
forms of microglial activation either due to common preceding
events (e.g., angina preceding a myocardial infarction) or more
directly. However, it should also be recognized that the under-
standing of microglial activation states is incomplete (Hanisch and
Kettenmann, 2007; Kettenmann et al., 2013), making the identiﬁ-
cation and use of state-speciﬁc markers difﬁcult.
Because studying human microglial function is challenging, we
also used publicly available monocyte, dendritic cell, and macro-
phage microarray data sets to explore TREM2 expression and assess
the validity of these cell types in modeling TREM2 function in hu-
man brain (Barreiro et al., 2012; Fairfax et al., 2012; Smith et al.,
2009). In agreement with the existing literature, we detected
TREM2 in dendritic cells and macrophages, but not in monocytes
(Colonna, 2003). Although we were able to identify a TREM2-
containing module in both dendritic cells and macrophages, there
was no signiﬁcant overlap in gene membership among the 2 celltypes. There was evidence for weak but signiﬁcant overlap in the
TREM2-containing modules in macrophages and brain (as repre-
sented by the TREM2-containing module in the hippocampus). On
deeper inspection, the major common element between these
modules was the signiﬁcant enrichment of lysosome-related genes.
These ﬁndings suggest that using macrophages and dendritic cells
to study TREM2 function in human brain may not be helpful.
Furthermore, these ﬁndings highlight the unique properties of
microglia, as compared to related myeloid cell types, in keeping
with their distinct developmental origin (Chan et al., 2007).
As a result of these ﬁndings, we focused our efforts on studying
the features of the TREM2-containing modules in human brain. We
found that TREM2 was a hub gene in 5 brain regions, namely, the
hippocampus, white matter, substantia nigra, and putamen, sug-
gesting that TREM2 is capable of drivingmicroglial functions in these
regions. Although these ﬁndings do not fully explain the regional
distribution of pathology in either Nasu-Hakola disease or AD, the
“hub” role of TREM2 in white matter and hippocampus is certainly
consistent with the severe leukoencephalopathy in the former and
the selective loss of hippocampal neurons that characterize the latter.
Using GO enrichment analysis to investigate module membership,
we conﬁrmed the well-recognized role of TREM2 in the innate im-
mune response and related that to lysosome activity. However, this
analysis also revealed the signiﬁcant enrichment of genes related to
lymphocyte activity (T and B cell), antigen presentation and cytokine
release, which may be equally important in human brain.
To obtain further insights into TREM2-related signaling, we
focused on a “core” group of 156 TREM2-related genes and used this
gene list to look for enrichment of canonical gene sets deﬁned by
KEGG and relating to known pathways. Using this approach we
identiﬁed 2 independent pathways of interest, the “Fc gamma
R-mediated phagocytosis” and “Systemic lupus erythematosus”
pathways. Because canonical pathways are limited by our existing
knowledge base, we also visualized gene connectivity within the
TREM2-containing module using VisANT in hippocampus and cer-
ebellum. This approach not only identiﬁed genes highlighted
within the KEGG pathways, but also identiﬁed additional genes of
interest based on their high connectivity to TREM2 particularly in
the hippocampus. The predominant common theme among these
genes is their involvement in cytoskeletal regulation. For example,
NCKAP1L (also known as HEM1), a member of the Scar/WAVE
complex, plays an important role in regulating cell shape, and is
essential in neutrophil chemotaxis (Weiner et al., 2006). Similarly
DOCK2 is known to be involved in remodeling of the actin cyto-
skeleton required for lymphocyte migration (Sanui et al., 2003) and
the biological functions of DOCK8, include regulation of cell
migration (Harada et al., 2012; Jabara et al., 2012; Lambe et al.,
2011). Interestingly, disruptions in this gene have also been linked
to mental retardation and developmental disabilities (Griggs et al.,
2008). APBB1IP encodes the Rap1eGTP-interacting adaptor mole-
cule (RIAM) and is involved in mediating changes in the actin
cytoskeleton after integrin-mediated adhesion, and is already a
candidate gene for late-onset AD based on linkage analyses at
chromosome 10 (Hernandez-Varas et al., 2011; Lafuente et al.,
2004; Morgan et al., 2007).
This approach also highlighted a range of damage-related sig-
nals, namely C1Q complexes, ATP/ADP, and CSF-1, through the
identiﬁcation of C1QB, P2RY12, P2RY13, and CSF1R. Although the
role of C1Q in microglial activation is well understood, there is
emerging evidence for purinergic signaling. Activation of the
P2RY12 is of key importance in mediating the chemotactic response
of microglia to ATP/ADP released from apoptotic cells (Haynes et al.,
2006; Pocock and Kettenmann, 2007). CSF1R, which encodes a cell
surface receptor primarily for the cytokine CSF-1, regulates the
survival, proliferation, differentiation, and function of mononuclear
P. Forabosco et al. / Neurobiology of Aging 34 (2013) 2699e27142712phagocytic cells, including microglia, and this gene is of particular
interest because the TREM2-TYROBP protein complex has recently
been implicated in CSF1R signaling (Otero et al., 2009). Further-
more, mutations in this gene are a cause of hereditary diffuse leu-
koencephalopathy with spheroids (HDLS), an autosomal-dominant
central nervous systemwhite matter disease with some features in
commonwith Nasu-Hakola disease (Rademakers et al., 2011). Thus,
combining these 2 major themes (i.e., damage-related signals and
cytoskeletal regulation) would suggest that TREM2 plays a key role
in mediating changes in the microglial cytoskeleton required to
initiate not only phagocytosis of apoptotic material but also other
processes such as microglial migration to injury or plaque deposi-
tion sites (Nimmerjahn et al., 2005).
Finally, but most importantly, we demonstrate a signiﬁcant
enrichment of genes already implicated in AD, MS, and, to a lesser
extent, MND (as documented by the HUGEnavigator database (Yu
et al., 2008)) among the core genes of the TREM2-containing gene
modules of human brain. This ﬁnding is important for 3 reasons.
First, it places a number of known AD risk genes, namely MS4A6A
and TREM2, in the same functional gene module, allowing us to
begin to identify important pathophysiological pathways as
opposed to single genes. Second, the enrichment of knownMS, and
to a lesser extent, MND-related genes (but not PD-related genes)
suggests that the traditional classiﬁcation of primary and secondary
neurodegenerative diseases may be artiﬁcial and that the under-
lying pathophysiological processes converge (in at least a subset of
neurological disorders) and center on microglial function. Third,
this analysis implies that among the list of identiﬁed genes, there
may as yet unidentiﬁed risk genes for AD and potentially other
neurological disorders. Thus, this study provides important insights
into TREM2-related signaling, which could be used as a platform for
further experiments into the pathophysiological basis of late-onset
Alzheimer’s disease.
Disclosure statement
The authors have no conﬂicting ﬁnancial, personal, or profes-
sional interests.
Acknowledgements
This work was supported by the MRC through the MRC Sudden
Death Brain Bank (C.S.) and by a Project Grant (G0901254 to J.H. and
M.W.) and Training Fellowship (G0802462 toM.R.). The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. Funding to pay the Open
Access publication charges for this article was provided by Medical
Research Council UK.
Deﬁnitions
Adjacency matrix
The adjacency matrix deﬁnes the co-expression network. It is
constructed here from the pairwise Pearson correlations between
all genes, raising these correlations to a power beta while main-
taining the information on the correlation signs between genes,
thus constructing a signed weighted co-coexpression network.
Connectivity
For each gene, the connectivity (also known as degree) is
deﬁned as the sum of its adjacencies with the other network genes.
In co-expression networks, the connectivity measures how corre-
lated a gene is with all other network genes.Topological overlap matrix (TOM)
Topological overlap measure (TOM) is a pairwise measure of
node similarity, that measures how close the neighbors of a gene
are to the neighbors of the other gene. Unlike correlation or adja-
cency measures, which consider each pair of genes in isolation,
TOM considers each pair of genes in relation to all other genes in the
network, and it reﬂects the relative interconnectedness of 2 nodes
within their local neighbourhood.
Module eigengene (ME)
The module eigengene is deﬁned as the ﬁrst principal compo-
nent of the expression proﬁles of all genes in a given module.
Module membership (MM)
For each gene, the module membership (also known as
eigengene-based connectivity) is calculated as the correlation of the
gene expression proﬁle with the module eigengene (ME) of a given
module. If MM of a gene for a given module is close to 0, it means
that the gene is not part of that module. On the other hand, if MM is
close to 1 or 1, it is highly connected to the module genes. The sign
of module membership encodes whether the gene has a positive or
a negative relationship with the module eigengene. Highly con-
nected intramodular hub genes tend to have high module mem-
bership values to the respective module.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.
2013.05.001.
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